ACOR Acorda Therapeutics, Inc.

25.30
+0  (0%)
Previous Close 25.30
Open 25.15
Price To book 1.73
Market Cap 1.15B
Shares 45,500,000
Volume 542,234
Short Ratio 8.30
Av. Daily Volume 735,350

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Decision on Inter Partes Review (IPR) expected March 2017. Legal event (non-clinical).
Ampyra
Phase 2 to be initiated by the end of 2017.
CVT-427
Migraine
Phase 3 data due 1Q 2018.
Tozadenant
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Dalfampridine
Post stroke deficits
Phase 3 data released February 9, 2017 - primary endpoint met.
CVT-301
OFF episodes of Parkinson’s disease (PD)

Latest News

  1. Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors
  2. Generic Competitors A Looming Threat For Acorda Therapeutics Inc (ACOR)
  3. Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017
  4. Acorda Must Stave Off Mylan, Teva Generics To Protect Ampyra: RBC
  5. Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017
  6. Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4
  7. Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.
  8. Acorda Therapeutics upgraded by Goldman
  9. Edited Transcript of ACOR earnings conference call or presentation 14-Feb-17 1:30pm GMT
  10. The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
  11. Acorda Therapeutics Inc Earnings Call scheduled for 8:30 am ET today
  12. Q4 2016 Acorda Therapeutics Inc Earnings Release - Before Market Open
  13. ACORDA THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
  14. Acorda reports 4Q loss
  15. Acorda reports 4Q loss
  16. Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016
  17. A Loud Coaching Session on the Desk
  18. Acorda (ACOR) Catches Eye: Stock Gains 20.8% in Session
  19. Blog Coverage Acorda's Stock Price Soared Above 20% on Positive Data from Parkinson Disease Late Stage Clinical Trial